IFFO1 and neoplasm: IFFO1 is downregulated in OC to confer cisplatin resistance, tumor progression, and metastasis, and overexpressed IFFO1 hinders the β-catenin translocation to nucleus, resulting in reduced metastasis and enhanced sensitivity to cisplatin.